Teneligliptin hydrobromide hydrate was approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on June 29, 2012. It was co-developed & co-marketed as Tenelia^® by Mitsubishi Tanabe and Daiichi Sankyo. Teneligliptin hydrobromide hydrate is a dipeptidyl peptidase-4 inhibitor. It is indicated for the treatment of type 2 diabetes. Tenelia^® is available as tablet for oral use, containing 20 mg of free Teneligliptin, and the recommended dose is 20 mg (40 mg if insufficient) once daily for adults. Removal of impurities from API manufacturing is an integral part of drug manufacturing. KarpsChem has specialization in synthesis / supply of pharmacopoeia impurities, process impurities, isolation and identification of unknown impurities of Teneligliptin to all pharmaceutical companies in India and overseas. Critical impurities of Teneligliptin like Teneligliptin Impurity A (CAS No: 401566-79-8);  Teneint-G; Teneligliptin intermediate B (CAS No: 401564-36-1); Teneligliptin (2R,4R)-Isomer (CAS No:1404559-17-6 (Free Base)); Teneligliptin Impurity B (CAS No: 401566-80-1); Teneligliptin Impurity C or Tert-butyl (2S)-4-hydroxy-2-(thiazolidine-3-carbonyl) pyrrolidine-1-carboxylate are notable contribution of KarpsChem in synthetic outcome. Other than impurity synthesis recently, KarpsChem has also triumph synthesis of Teneligliptin intermediate B standard (CAS No: 401564-36-1) i.e. (2S)-4-Oxo-2-(3-thiazolidinylcarbonyl)-1-pyrrolidinecarboxylic acid tert-butyl ester. For instant quote log on to: www.karpschem.in | Contact: info@karpschem.in |  +91-7249203006